RecruitingPhase 4NCT06609304

Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

Prospective Clinical Study of Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

Sponsor

Zhengzhou University

Enrollment

20 participants

Start Date

Sep 30, 2024

Study Type

INTERVENTIONAL

Conditions

Lymphoma, B-Cell

Summary

The goal of this clinical trial is to learn if Axicabtagene Ciloleucel (axi-cel) works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of axi-cel treatment. The main questions it aims to answer are: * Does axi-cel treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment? * What medical problems do participants have when receiving axi-cel treatment? In this investigator-initiated, single-arm clinical trial, participants will: * Receive atezolizumab treatment at 2.0×10\^6 cells/Kg as a one-time therapy. * Visit the clinic as instructed for checkups and tests.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying whether a CAR-T cell therapy called axicabtagene ciloleucel (Yescarta) can be used as a "consolidation" treatment after first-line chemotherapy for patients with high-risk large B-cell lymphoma (an aggressive blood cancer). CAR-T therapy involves re-engineering a patient's own immune cells to attack cancer. Researchers want to see if using it early prevents relapse. **You may be eligible if...** - You are between 18 and 70 years old - You have been newly diagnosed with large B-cell lymphoma that tests positive for CD19 - You have not been treated for this lymphoma before - You are in good physical condition (ECOG 0 or 1) - Your organs and bone marrow are functioning adequately **You may NOT be eligible if...** - You have had a prior stem cell or organ transplant - You have active infections - Your lymphoma has spread to the brain or central nervous system - You have received prior CAR-T or modified T-cell therapy - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.